Suppliers and packagers for DOBUTAMINE HYDROCHLORIDE

DOBUTAMINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hikma	DOBUTAMINE HYDROCHLORIDE	dobutamine hydrochloride	INJECTABLE;INJECTION	074277	ANDA	Hikma Pharmaceuticals USA Inc.	0143-9141-10	10 VIAL in 1 CARTON (0143-9141-10) / 20 mL in 1 VIAL	2023-05-03
Hospira	DOBUTAMINE HYDROCHLORIDE	dobutamine hydrochloride	INJECTABLE;INJECTION	074086	ANDA	Hospira, Inc.	0409-2344-88	10 VIAL, SINGLE-DOSE in 1 TRAY (0409-2344-88) / 20 mL in 1 VIAL, SINGLE-DOSE (0409-2344-68)	2005-04-30
Hospira	DOBUTAMINE HYDROCHLORIDE	dobutamine hydrochloride	INJECTABLE;INJECTION	074086	ANDA	Hospira, Inc.	0409-2344-01	1 VIAL, SINGLE-DOSE in 1 CARTON (0409-2344-01) / 20 mL in 1 VIAL, SINGLE-DOSE	2005-04-30

Dobutamine Hydrochloride Suppliers: Market Landscape and Strategic Sourcing

Last updated: February 19, 2026

Dobutamine hydrochloride is an inotropic agent primarily used to treat cardiac decompensation. Key suppliers are concentrated in China and India, with a smaller presence in Europe. Raw material availability, regulatory compliance, and manufacturing capacity are critical sourcing considerations.

What is the Global Market Status for Dobutamine Hydrochloride?

The global market for dobutamine hydrochloride is characterized by a moderate but stable demand, driven by its essential role in managing acute heart failure and cardiogenic shock. The market is primarily supplied by a limited number of manufacturers, with a significant concentration in Asia.

Key Market Dynamics:

• Demand Drivers:
  • Prevalence of cardiovascular diseases, including heart failure.
  • Use in post-operative cardiac care and diagnostic procedures.
  • Emerging markets' increasing access to advanced medical treatments.
• Supply Chain Concentration:
  • Major manufacturing hubs are located in China and India, leveraging cost advantages and established chemical synthesis infrastructure.
  • A smaller number of European manufacturers contribute to the supply, often focusing on higher-purity grades or specialized formulations.
• Regulatory Landscape:
  • Manufacturers must adhere to stringent Current Good Manufacturing Practices (cGMP) mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
  • Drug Master Files (DMFs) are essential for market entry in regulated territories.
• Price Sensitivity:
  • As an established drug, pricing is competitive. Raw material costs and production efficiency significantly influence final product pricing.
• Generic Competition:
  • Dobutamine hydrochloride is a generic drug, leading to a competitive market where reliable supply and quality are paramount.

Who are the Primary Manufacturers of Dobutamine Hydrochloride?

The manufacturing of dobutamine hydrochloride is dominated by companies with expertise in active pharmaceutical ingredient (API) synthesis and adherence to international quality standards.

Leading Manufacturers:

Manufacturer Name	Country	Primary Products
Zhejiang Xianju Pharma	China	Dobutamine Hydrochloride API
CSPC Pharmaceutical Group	China	Dobutamine Hydrochloride API and Intermediates
Jiangsu Hengrui Pharma	China	Dobutamine Hydrochloride API
Sun Pharmaceutical Industries	India	Dobutamine Hydrochloride API
Dr. Reddy's Laboratories	India	Dobutamine Hydrochloride API
Sanofi S.A.	France	Dobutamine Hydrochloride (Finished Dosage Form)
Fresenius Kabi	Germany	Dobutamine Hydrochloride (Finished Dosage Form)

Note: Sanofi and Fresenius Kabi are primarily known for finished dosage forms, but their integrated supply chains may involve in-house API production or strict supplier management.

What are the Key Raw Materials and Intermediates?

The synthesis of dobutamine hydrochloride requires specific precursor chemicals and intermediates. The availability and quality of these materials directly impact the production of the final API.

Essential Raw Materials and Intermediates:

• 4-(p-hydroxyphenyl)-2-butanone: A critical ketone intermediate in the synthesis pathway.
• tert-Butylamine: Used in the reductive amination step.
• Formaldehyde: Another key reagent in the synthesis.
• Hydrochloric Acid: Used for salt formation, yielding the hydrochloride form.
• Solvents: Various organic solvents such as methanol, ethanol, and toluene are used throughout the manufacturing process.
• Catalysts: Specific catalysts are employed to facilitate reaction steps.

Supply chain resilience for these intermediates is crucial. Disruptions in the availability of any of these components can halt production.

What are the Regulatory Requirements for Dobutamine Hydrochloride Production?

Compliance with stringent regulatory guidelines is non-negotiable for dobutamine hydrochloride API manufacturers. These requirements ensure product quality, safety, and efficacy.

Key Regulatory Standards:

• Current Good Manufacturing Practices (cGMP): Manufacturers must adhere to cGMP guidelines as defined by regulatory bodies like the FDA (21 CFR Parts 210 & 211) and EMA. This covers all aspects of production, including facility design, equipment validation, personnel training, process controls, and quality assurance.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality controls. Pharmaceutical companies reference these DMFs when seeking approval for their finished drug products.
• Pharmacopoeial Standards: Dobutamine hydrochloride must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP). These monographs define purity, identity, and assay requirements.
• Impurity Profiling: Rigorous control and characterization of process-related impurities and degradation products are essential.
• Stability Studies: Manufacturers must conduct comprehensive stability studies to determine the shelf-life and recommended storage conditions for the API.

What are the Strategic Sourcing Considerations for Dobutamine Hydrochloride?

Sourcing dobutamine hydrochloride requires a strategic approach that balances cost, quality, reliability, and regulatory compliance.

Critical Sourcing Factors:

• Quality and Compliance:
  • Verify that the supplier's manufacturing site is regularly audited and compliant with cGMP standards.
  • Review Certificates of Analysis (CoAs) for each batch to ensure it meets pharmacopoeial and customer-specific requirements.
  • Assess the supplier's impurity profiles and control strategies.
• Supply Chain Reliability:
  • Evaluate the supplier's production capacity and track record for on-time delivery.
  • Understand their raw material sourcing and inventory management practices.
  • Identify potential single points of failure in their supply chain.
• Cost Competitiveness:
  • Obtain quotes from multiple qualified suppliers.
  • Consider total cost of ownership, including shipping, customs, and quality control testing.
  • Negotiate long-term supply agreements to secure favorable pricing and supply guarantees.
• Regulatory Support:
  • Confirm the availability of a DMF or equivalent documentation for the target market.
  • Assess the supplier's responsiveness to regulatory inquiries and audits.
• Geographic Diversification:
  • Consider sourcing from suppliers in different geographic regions to mitigate risks associated with geopolitical instability, natural disasters, or regional regulatory changes. For example, balancing Chinese or Indian suppliers with a European option.
• Auditing and Due Diligence:
  • Conduct thorough site audits of potential suppliers to verify manufacturing processes, quality systems, and adherence to ethical labor practices.
  • Review financial stability and business continuity plans.

What are the Potential Risks in the Dobutamine Hydrochloride Supply Chain?

The supply chain for dobutamine hydrochloride, like many pharmaceutical APIs, is susceptible to various risks that can impact availability and cost.

Key Supply Chain Risks:

• Regulatory Changes: Sudden shifts in regulatory requirements in manufacturing countries or target markets can disrupt production or necessitate costly process modifications.
• Raw Material Shortages: Dependence on specific chemical intermediates can lead to shortages if their own supply chains are compromised by manufacturing issues, environmental regulations, or geopolitical events.
• Quality Incidents: Manufacturing deviations, contamination events, or out-of-specification batches can lead to product recalls, supply disruptions, and reputational damage for both the supplier and the pharmaceutical company.
• Geopolitical Instability: Trade disputes, export restrictions, or political unrest in key manufacturing regions can significantly impact the flow of goods.
• Environmental Regulations: Increasingly stringent environmental regulations in China and India can lead to temporary plant shutdowns or increased operational costs for API manufacturers.
• Logistics and Transportation: Delays in shipping, increased freight costs, or disruptions in global logistics networks can affect delivery times and inventory management.
• Intellectual Property and Counterfeiting: While dobutamine hydrochloride is a generic drug, ensuring the authenticity and integrity of the supply chain is crucial to prevent the introduction of substandard or counterfeit products.

Key Takeaways

• Dobutamine hydrochloride manufacturing is concentrated in China and India, with a few European players.
• Key suppliers include Zhejiang Xianju Pharma, CSPC Pharmaceutical Group, Jiangsu Hengrui Pharma, Sun Pharmaceutical Industries, and Dr. Reddy's Laboratories.
• Regulatory compliance (cGMP, DMFs, pharmacopoeial standards) is paramount.
• Strategic sourcing requires balancing quality, supply reliability, cost, and regulatory support.
• Potential risks include regulatory changes, raw material shortages, quality incidents, and geopolitical instability.

Frequently Asked Questions

1. What is the typical lead time for dobutamine hydrochloride API orders? Lead times can vary but generally range from 8 to 16 weeks, depending on the supplier's existing production schedule, order volume, and raw material availability.
2. Are there any specific certifications required beyond cGMP for dobutamine hydrochloride suppliers? While cGMP is the primary requirement, suppliers may also hold ISO certifications (e.g., ISO 9001 for quality management) and undergo specific customer audits related to their quality management systems and supply chain security.
3. How can I verify the quality of dobutamine hydrochloride API from a new supplier? Verification involves reviewing the supplier's DMF, their recent audit reports, Certificates of Analysis for multiple batches, and performing independent third-party testing of initial material shipments.
4. What are the implications of the European Pharmacopoeia (EP) monograph updates on dobutamine hydrochloride? Updates to the EP monograph can introduce new testing requirements or tighter specifications for impurities. Suppliers must ensure their manufacturing processes and quality control methods align with the latest EP standards to remain compliant for the European market.
5. Can I source dobutamine hydrochloride intermediates from a different supplier than the final API manufacturer? Yes, it is possible to source intermediates independently, but this adds complexity. It requires rigorous qualification of both the intermediate supplier and the API manufacturer to ensure compatibility and that the API manufacturer has full control over the quality of the incoming intermediates.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [FDA Website] (Specific URL for CGMP regulations would be linked if available). [2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [EMA Website] (Specific URL for GMP guidelines would be linked if available). [3] United States Pharmacopeia. (n.d.). Dobutamine Hydrochloride Monograph. (Access requires subscription to USP-NF). [4] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). European Pharmacopoeia. (Access requires subscription to Ph. Eur.). [5] Publicly available company information and market research reports from financial data providers like Bloomberg, Refinitiv, and industry-specific market intelligence firms. (Specific report titles and dates would be cited if directly referenced).